Levodopa

Handbook of Parkinson's Disease, Third Edition

Volumn , Issue , 2003, Pages 381-405

  Santiago, Anthony J ^a   Factor, Stewart A ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85047993367     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (91)

1. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones, 1817.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.
3. Factor SA. Parkinson’s disease: initial treatment with levodopa or dopamine agonists. Curr Treat Options 2001; 3:479-493.
4. Doshay L, Constable K. Newer drugs in the treatment of Parkinsonism. Neurology 1951; 1:68-74.
5. Epidemic Encephalitis. Report of a Survey by the Matheson Commission, New York, Columbia University Press, 1939.
6. Von Witzleben H. Methods of Treatment in Postencephalitic Parkinsonism. New York: Grune &Stratton, Inc., 1942.
7. Doshay L. Recent trends in the treatment of epidemic encephalitis. NYS J Med 1934; 34:707.
8. Foley P. The L-dopa story revisited. Further surprises to be expected? J Neur Transm Suppl 2000; 60:1-20.
9. Funk C. Synthase des d,1-3-4, Dioxyphenylalanins. Chem Zentralbl I, 1911.
10. Guggenhiem M. Dioxyphenylalanin, eine neue Aminoshure aus Vicia faba. Z Phys Chem, 1913.
11. Carrlson A, Lindqvist M, Magmusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytriptophan as reserpine antagonists. Nature (London) 1957; 180:1200.
12. Carrlson A, Linqvist M, Magmussen T, Waldbeck B. On the presence of 3-hydroxytyramine in the brain. Science 1958; 127:471.
13. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin im Gehirn des Menschwen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenscher 1960; 38:1236-1239.
14. Cotzias G, Van Woert M, Schiffer L. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379.
15. Cotzias G, Papavasiliou P, Gellene R. Modification of parkinsonism—chronic treatment with L-DOPA. N Engl J Med 1969; 280:337-345.
16. Kapp W. The history of drugs for the treatment of Parkinson’s disease. J Neural Transm 1992; 38:1-6.
17. Rinne U, Sonninen V, Siirtola T. Treatment of parkinsonian patients with levodopa and estracerebral decarboylase inhibitor, Ro 4-4062. Adv Neurol1973; 3:59-71.
18. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310(8):483-488.
19. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and syndromes of Parkinson and Huntington. J Neurol Sci1975; 30:415-455.
20. Muenter M, Tyce G. L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response and side effects. Mayo Clin Proc 1971; 46:231-239.
21. Melamed E, Hefti F, Wurtman RJ. Nondopaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 1980; 8:558-563.
22. Poewe W, Wenning G. Levodopa. Parkinson’s disease: mechanisms of action, pathophysiology of late failure. In: Parkinson’s Disease and Movement Disorders. Jankovic J, Tolosa E, eds. Baltimore: Williams and Wilkins, 1998, pp 177-190.
23. Fahn S. Parkinson’s disease, the effect of levodopa and the ELLDOPA trial. Arch Neurol 1999; 56:529-535.
24. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cummulative literature. Mov Disord2001; 16(3):448-458.
25. Nutt J, Carter J, Woodward W. Long-duration response to levodopa. Neurology 1995; 45:1613-1616.
26. Nutt J. Motor Fluctuations and dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 2001; 8:101-108.
27. Nutt J. Pharmacodynamics of levodopa in Parkinson’s disease. Clin Exp Pharmacol Physiol 1995; 22:837-840.
28. Nutt J, Gancher S, Woodward W. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38:1553-1557.
29. Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S, Leiguarda R. Sleep benefit in Parkinson’s disease. Mov Disord 1997; 12:506-508.
30. Simuni T, Hurtig H. Levodopa: 30 years of progress. In: Parkinson’s Disease: Diagnosis and Clinical Management. Factor SA, Weiner WJ, eds. New York: Demos, 2002:339-356.
31. Yahr MD. Levodopa. Ann Int Med 1975; 83:677-682.
32. Sweet RD, McDowell FH. Five years’ treatment of Parkinson’s disease with levodopa: therapeutic results and survival of 100 patients. Ann Int Med 1975; 83:456-463.
33. Rajput AH, Stern W, Laverly WH. Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology1984; 34:991-996.
34. Poewe WH, Lees AJ, Stern GM. Low dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
35. Koller WC, Hutton JT, Tolosa E, Capilldeo R, and the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999; 53:1012-1019.
36. Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA 2000; 284:1931-1938.
37. Holloway RG. Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a four-year randomized controlled trial. Neurology2002; 58(suppl 3):A81-82.
38. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole versus levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661.
39. Marek K. Pramipexole versus levodopa: effects on Parkinson disease progression assessed by dopamine transporter imaging. Neurology 2002; 58(suppl 3):A82.
40. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 42:1484-1491.
41. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa controlled study. Mov Disord 1998; 13:39-45.
42. Barbeau A. Long-term appraisal of levodopa therapy. Neurology 1972; 22(suppl):22-24.
43. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long term therapy. Neurology 1979; 29:1253-1260.
44. de Jong GJ, Meerwaldt JD, Schmitz PIM. Factors that influence the occurence of response variations in Parkinson’s disease. Ann Neurol 1987; 22:4-7.
45. Cedarbaum JM, Gandy SE, McDowell FH. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia or dementia in Parkinson’s disease. Neurology 1991; 41:622-629.
46. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson’s disease?Neurology 1988; 38:1410-1416.
47. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991; 41:380-384.
48. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19:253-264.
49. Horstink MWIM, Zijlmans JCM, Pasman JW, Berger HJC, van’t Hof MA. Severity of Parkinson’s disease is a risk factor for peak dose dyskinesia. J Neurol Neurosurg Psychiatry 1990; 59:224-226.
50. Roos RAC, Vredevoogd CB, van der Velde EA. Response fluctuations in Parkinson’s disease. Neurology 1990; 40:1344-1346.
51. Kostic VS, Marinkovic J, Svetel M, Stfanova E, Przedborski S. The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2000; 9:9-14.
52. Langston JW. The impact of MPTP on Parkinson’s disease research: past, present and future. In: Parkinson’s Disease: Diagnosis and Clinical Management. Factor SA, Weiner WJ, eds. New York: Demos, 2002:299-329.
53. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol1998; 43:551-554.
54. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson’s disease: Central pathophysiological mechanisms, part I. Ann Neurol 1988; 24:366-371.
55. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson’s disease: Contributions of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
56. Mouradian MM, Juncos JL, Fabbrini G, et al: Motor fluctuations in Parkinson’s disease: Central pathophysiological mechanisms, part II. Ann Neurol 1988; 24:372-378.
57. Mouradian MM, Heuser JE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 1990; 27:18-23.
58. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until advanced stages of the disease. Arch Neurol 1986; 43:402-405.
59. Shulman LM. Levodopa toxicity in Parkinson’s disease: reality or myth? Reality—practice patterns should change. Arch Neurol 2000; 57:406-407.
60. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992; 32:804.
61. Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology 1990; 40(suppl 3):32-37.
62. Calne DB. The free radical hypothesis in Parkinson’s disease: evidence against it. Ann Neurol 1992; 32:799.
63. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50:858-863.
64. Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998; 351:851-852.
65. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson’s disease: a consensus meeting. Mov Disord 1999; 14:911-913.
66. Fahn S. Is levodopa toxic? Neurology 1996; 47(suppl 3):S184-S195.
67. Olney JW, Zorumski CF, Stewart GR, et al. Excitotoxicity of L-DOPA and 6-OH-DOPA: implications for Parkinson’s and Huntington’s diseases. Exp Neurol 1990; 108:269-272.
68. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993; 34:715-723.
69. Ziv I, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson’s disease? Mov Disord 1997; 12:17-23.
70. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology1981; 31:1194-1195.
71. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984; 43:990-993.
72. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility and longevity. Science 1977; 196:549-551.
73. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8:129-133.
74. Murer MG, Dziewczapolski G, Menalled, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43:561-575.
75. Fukuda T, Watabe K, Tanaka J. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996; 728:274-276.
76. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions. Mov Disord 2001; 16:424-434.
77. Quinn NP, Parkes D, Janota I, Marsden CD. Case report: preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa (2 g) plus a decarboxylase inhibitor over a four-year period. Mov Disord 1986; 1:65-68.
78. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997; 12:634-638.
79. Yahr MD, Wolf A, Antunes J-L, et al. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972; 22(suppl):56-71.
80. Gwinn-Hardy K, Evidente VGH, Waters C, Muenter MD, Hardy J. L-dopa slows the progression of familial parkinsonism. Lancet 1999; 353:1850-1851.
81. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 1981; 31:125-131.
82. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson’s disease. Ann Neurol 1986; 19:365-372.
83. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22:8-12.
84. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease. Neurology 1990; 40:265-269.
85. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project. Neurology 1993; 43:1918-1926.
86. Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol 1998; 38:782-784.
87. Woofter M, Manyam B. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol 1994; 17:315-319.
88. Weiner W, Singer C, Sanchez-Ramos J, Goldenberg J. Levodopa, melanoma and Parkinson’s Disease. Neurology 1993; 43:674-677.
89. Siple J, Schneider D, Wanlass W, Rosenblatt B. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000; 34:382-385.
90. Clarke C, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000; 69:590-594.
91. Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. Acute challenge with apomorphine and levodopa in parkinsonism. Eur Neurol 2000; 43:95-101.